Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
253 stopped studies mapped to Malignant Endocrine Neoplasm and descendants · 91% state a reason
Over the 253 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04750239 | Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell… | Phase 1 / Phase 2 | terminated | Feb 11, 2021 | Y-mAbs Therapeutics | Study terminated due to business priorities | Sponsor / business decision |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in…(ALpha-T) | Phase 2 | terminated | Nov 25, 2020 | Hoffmann-La Roche | The data from this study is no longer needed. | Other (stated, no rule matched) |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver… | Phase 2 | terminated | Jan 9, 2014 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT05411679 | EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell… | Phase 2 | withdrawn | Jun 9, 2022 | Ellipses Pharma | Futility analysis decision to terminate EP0057 compound and all Ellipses sponsored studies… | Efficacy / futility |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch…(REFIT-MSS) | Phase 2 | withdrawn | Oct 17, 2022 | Translational Research in Oncology | Study never started/ will not proceed. | Other (stated, no rule matched) |
| NCT02036476 | Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma | Phase 2 | terminated | Jan 15, 2014 | Dana-Farber Cancer Institute | Lack of accrual. | Enrollment / accrual |
| NCT03488472 | Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain(RAD 1704) | N/A | terminated | Apr 5, 2018 | Drexell Hunter Boggs | This feasibility study only accrued one patient since site activation. We believe that the primary… | Enrollment / accrual |
| NCT04590781 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or… | Phase 1 / Phase 2 | terminated | Oct 19, 2020 | Xencor, Inc. | The study has been terminated early by the sponsor due to business decision. | Sponsor / business decision |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory… | Phase 1 | terminated | Sep 7, 2016 | Pfizer | not stated | Not stated |
| NCT03406715 | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With… | Phase 2 | terminated | Jan 23, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Sponsor closed study | Other (stated, no rule matched) |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With…(REVEAL) | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Nektar Therapeutics | Based on the overall results from the Phase 1 part of the study the sponsor decided to end the… | Safety / toxicity |
| NCT02963090 | Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | Phase 2 | terminated | Nov 15, 2016 | Alliance Foundation Trials, LLC. | Lack of enrollment | Enrollment / accrual |
| NCT04447014 | Natural History Study of Children and Adults With Adrenocortical Cancer (ACC) | — | terminated | Jun 25, 2020 | National Cancer Institute (NCI) | To avoid the duplication of resources and effort associated with the PI switching branches. | Other (stated, no rule matched) |
| NCT04488263 | Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s | — | terminated | Jul 27, 2020 | National Cancer Institute (NCI) | To avoid the duplication of effort and resources associated with the PI's branch change. | Other (stated, no rule matched) |
| NCT03506048 | Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive… | Phase 2 | terminated | Apr 23, 2018 | Emory University | Study has been abandoned for lack of accrual | Enrollment / accrual |
| NCT01266018 | Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung… | Phase 2 | terminated | Dec 24, 2010 | Ludwig Institute for Cancer Research | Lack of efficacy in Cohort 2; slow enrollment in Cohort 1 | Efficacy / futility |
| NCT04022876 | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects… | Phase 1 | terminated | Jul 17, 2019 | Aileron Therapeutics, Inc. | With a favorable safety profile the difference between treatment groups for the primary composite… | Safety / toxicity |
| NCT02363647 | Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic… | N/A | terminated | Feb 16, 2015 | Icahn School of Medicine at Mount Sinai | No Current Funding | Funding |
| NCT00637624 | N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing…(NAC-PNP) | N/A | terminated | Mar 18, 2008 | Rijnstate Hospital | Unable to recruit enough patients | Enrollment / accrual |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT04210037 | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung… | Phase 1 / Phase 2 | terminated | Dec 24, 2019 | Ascentage Pharma Group Inc. | Sponsor decision | Sponsor / business decision |
| NCT04173325 | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | Phase 1 | terminated | Nov 21, 2019 | Augusta University | Closed by the IRB 5/26/22 due to non-compliance | Other (stated, no rule matched) |
| NCT04841538 | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant… | Phase 1 / Phase 2 | withdrawn | Apr 12, 2021 | Elpiscience Biopharma, Ltd. | Sponsor's clinical development strategy adjustment | Sponsor / business decision |
| NCT00286169 | Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer… | Phase 3 | terminated | Feb 3, 2006 | Sumitomo Pharma Co., Ltd. | not stated | Not stated |
| NCT02584829 | Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without… | Phase 1 / Phase 2 | terminated | Oct 23, 2015 | Fred Hutchinson Cancer Center | Terminated due to loss in funding | Funding |
| NCT04525391 | AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer(SUKSES-N5) | Phase 2 | terminated | Aug 25, 2020 | Se-Hoon Lee | Recommended completion of the study due to SUSAR occurring in other clinical trials conducted with… | Other (stated, no rule matched) |
| NCT04874831 | Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic… | Phase 2 | withdrawn | May 6, 2021 | 4SC AG | Refocusing of sponsor's clinical development program. No safety concern or change of the… | Safety / toxicity |
| NCT02934503 | Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung… | Phase 2 | terminated | Oct 17, 2016 | NYU Langone Health | This study was terminated as the standard of care for small cell lung cancer changed in 2018 to… | Other (stated, no rule matched) |
| NCT04422210 | A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax… | Phase 1 | terminated | Jun 9, 2020 | Hoffmann-La Roche | Decision to discontinue the study based on broader development and strategic prioritisation. The… | Sponsor / business decision |
| NCT03838692 | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | Phase 2 | withdrawn | Feb 12, 2019 | Antonio Fojo | Closed by sponsor | Other (stated, no rule matched) |
| NCT04677361 | Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With… | Early Phase 1 | withdrawn | Dec 21, 2020 | Fox Chase Cancer Center | Grantor shifted focus in disease, funding was stopped | Funding |
| NCT03387332 | APG-1252 in Patients With SCLC or Advanced Solid Tumors | Phase 1 | terminated | Jan 2, 2018 | Ascentage Pharma Group Inc. | The company adjusts strategy. | Sponsor / business decision |
| NCT03988647 | Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma | Phase 2 | terminated | Jun 17, 2019 | Stanford University | Business decision | Sponsor / business decision |
| NCT03033511 | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line…(MERU) | Phase 3 | terminated | Jan 26, 2017 | AbbVie | Independent Data Monitoring Committee recommendation | Other (stated, no rule matched) |
| NCT03630120 | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | Phase 2 | terminated | Aug 14, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Lack of efficacy | Efficacy / futility |
| NCT01573338 | Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together… | Phase 1 / Phase 2 | terminated | Apr 9, 2012 | Bayer | not stated | Not stated |
| NCT02722369 | STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus… | Phase 2 | terminated | Mar 30, 2016 | University College, London | Low recruitment, lack of efficacy and increased adverse events in investigational arm. | Safety / toxicity |
| NCT04543916 | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | Phase 1 / Phase 2 | withdrawn | Sep 10, 2020 | Virginia Commonwealth University | AbbVie decided to stop trial involving Venetoclax for safety measures needed | Safety / toxicity |
| NCT03901378 | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade… | Phase 2 | withdrawn | Apr 3, 2019 | Ochsner Health System | Lack of accrual | Enrollment / accrual |
| NCT03516084 | A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based… | Phase 3 | terminated | May 4, 2018 | Zai Lab (Shanghai) Co., Ltd. | As the treatment model of extensive-stage small cell lung cancer changed rapidly and the enrollment… | Enrollment / accrual |
| NCT03042780 | FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas | Phase 2 | terminated | Feb 3, 2017 | H. Lee Moffitt Cancer Center and Research Institute | Slow accrual | Enrollment / accrual |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin…(NeoFIND) | Phase 2 | terminated | Oct 30, 2018 | Advanced Accelerator Applications | Recruitment was stopped before the target sample size was achieved. | Enrollment / accrual |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Mar 16, 2016 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT03116971 | Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC)… | Phase 1 | terminated | Apr 17, 2017 | EMD Serono Research & Development Institute, Inc. | Enrollment in the study was prematurely terminated due to recruitment challenges and not due to… | Safety / toxicity |
| NCT01859741 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum…(PINNACLE) | Phase 1 / Phase 2 | terminated | May 22, 2013 | OncoMed Pharmaceuticals, Inc. | OMP-59R5 did not improve PFS. | Other (stated, no rule matched) |
| NCT02315625 | Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced… | Phase 2 | terminated | Dec 12, 2014 | National Cancer Institute (NCI) | Study closed due to poor accrual. | Enrollment / accrual |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or… | Phase 2 | withdrawn | Sep 27, 2019 | M.D. Anderson Cancer Center | No Participants Registered | Other (stated, no rule matched) |
| NCT03607682 | Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With… | N/A | terminated | Jul 31, 2018 | Vanderbilt-Ingram Cancer Center | PI left institution and loss of funding | Investigator |
| NCT03026166 | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or… | Phase 1 / Phase 2 | terminated | Jan 20, 2017 | AbbVie | Enrollment was stopped after the dose-limiting toxicity (DLT) evaluation phase of Cohort 2. | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 14, 2023source: clinicaltrials